Compared with treatment options for early-stage breast cancer, few data exist regarding the optimal use of chemotherapy for metastatic breast cancer (MBC). The choice of using a combination of cytotoxic chemotherapies vs sequential single agents is controversial. At the 6th European Breast Cancer Conference, the European School of Oncology Metastatic Breast Cancer Task Force convened an open debate on the relative benefits of combination vs sequential therapy. Based on the available data, the Task Force recommends sequential monotherapy as the preferred choice in advanced disease, in the absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control. Patient- and disease-related factors should be used to choose between combination and sequential single-agent chemotherapy for MBC. Additional research is needed to determine the impact of therapy on patient-rated quality of life and to identify predictive factors that can be used to guide therapy.

International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy / Cardoso, F.; Bedard, P. L.; Winer, E. P.; PAGANI PALANCA INCORONATI, Oliva; Senkus-Konefka, E.; Fallowfield, L. J.; Kyriakides, S.; Costa, A.; Cufer, T.; Albain, K. S.. - In: JOURNAL OF THE NATIONAL CANCER INSTITUTE. - ISSN 0027-8874. - 101:17(2009), pp. 1174-1181. [10.1093/jnci/djp235]

International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy

PAGANI PALANCA INCORONATI, Oliva;
2009

Abstract

Compared with treatment options for early-stage breast cancer, few data exist regarding the optimal use of chemotherapy for metastatic breast cancer (MBC). The choice of using a combination of cytotoxic chemotherapies vs sequential single agents is controversial. At the 6th European Breast Cancer Conference, the European School of Oncology Metastatic Breast Cancer Task Force convened an open debate on the relative benefits of combination vs sequential therapy. Based on the available data, the Task Force recommends sequential monotherapy as the preferred choice in advanced disease, in the absence of rapid clinical progression, life-threatening visceral metastases, or the need for rapid symptom and/or disease control. Patient- and disease-related factors should be used to choose between combination and sequential single-agent chemotherapy for MBC. Additional research is needed to determine the impact of therapy on patient-rated quality of life and to identify predictive factors that can be used to guide therapy.
2009
Breast Cancer Conference, cytotoxic, chemotherapy
01 Pubblicazione su rivista::01a Articolo in rivista
International guidelines for management of metastatic breast cancer: Combination vs sequential single-agent chemotherapy / Cardoso, F.; Bedard, P. L.; Winer, E. P.; PAGANI PALANCA INCORONATI, Oliva; Senkus-Konefka, E.; Fallowfield, L. J.; Kyriakides, S.; Costa, A.; Cufer, T.; Albain, K. S.. - In: JOURNAL OF THE NATIONAL CANCER INSTITUTE. - ISSN 0027-8874. - 101:17(2009), pp. 1174-1181. [10.1093/jnci/djp235]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1311180
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 192
  • ???jsp.display-item.citation.isi??? 171
social impact